---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-031743"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2022-12-12T23:59:59+00:00"
generated_at: "2026-06-21T05:56:51.823105+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# FDA approves new manufacturing site for Cumberland's Sancuso; $1M milestone due

## Summary
- FDA approved Kindeva as new manufacturing and packaging site for Sancuso on Dec. 6, 2022.
- Cumberland acquired U.S. rights to Sancuso in Jan. 2022; Kyowa Kirin led the FDA submission.
- Cumberland will pay Kyowa Kirin a $1 million milestone payment following the approval.
- Sancuso is the first FDA-approved transdermal patch for chemotherapy-induced nausea/vomiting.

## SEC filing metadata
- accession: 0001628280-22-031743
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2022-12-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828022031743/0001628280-22-031743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828022031743/cpix-20221206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-031743
- JSON: https://secwatch.observer/filing/0001628280-22-031743.json
- Plain text: https://secwatch.observer/filing/0001628280-22-031743.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.